상세 보기
Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- ... Lee, Jae Hoon;
- 외 13명
Citations
WEB OF SCIENCE
0키워드
CLL; chronic lymphocytic leukemia; phase 3
- 제목
- Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
- 저자
- Ghia, Paolo; Pluta, Andrzej; Wach, Malgorzata; Lysak, Daniel; Kozak, Tomas; Simkovic, Martin; Kaplan, Polina; Kraychok, Iryna; Illes, Arpad; de la Serna, Javier; Dolan, Sean; Campbell, Philip; Musuraca, Gerardo; Jacob, Abraham; Avery, Eric J.; Lee, Jae Hoon; Wang, Denise; Patel, Priti; Jurczak, Wojciech
- 발행일
- 2020-09
- 유형
- Meeting Abstract
- 권
- 20
- 페이지
- S220 ~ S221
- 언어
- ENG
- 출판사
- CIG MEDIA GROUP, LP
- 발행국가
- 미국
- ISSN
- E 2152-2669
P 2152-2650